Hopper failed to raise funds for RAD and CHM, why would he change it here?
RAD got financially rescued by the CEO's intervention, CHM at this stage, is close to fall over. No strong CEO here who could / would intervene. The only way a deal would, or actually could be done is by finding someone interested in one or more of the assets. And exactly that is the problem. No partner to be seen.
7 CD19 CAR-Ts have been approved but only 2 are commercially used. Why? Because too expensive and complicated at this stage and like chemo, still just a temporarily fix. Of course, patients are thankful for every extra day without / less pain or even cancer free but the goal, a permanent cure, has been hardly achieved. CAR-Ts do not activate the immune system to take over and to take care of any reoccurrence. Hence so many patients with failed lines of treatment.
We've been told that B-cell and CF33 would deliver that outcome, but B-cell got put aside and apart of bile duct, we haven't had any CF33 meaningful results. Now tell me, why would anyone want to deal with IMU at this stage?
Like everyone here we want IMU to succeed as we all are directly or indirectly impacted by cancer but with every day passing that outcome becomes more and more less likely. And the money providing market is reflecting it. I had expected Hopper to raise when the cash fell below $100m, then at least when close to $50m. Who knows what the January 4C will show, 30m, 20m?
Time is running out to avoid a second CHM scenario and Hopper twice did not take the necessarily steps to avoid financial stress. One would have thought that the millions he invested via cap raisings would prevent those scenarios - No, not a tiny bit. He is worn out, tired and not the man with the MIDAS-TOUCH anymore. And that slow " decay " is reflected in the decisions made.
IMU holders have to cling on the hope of a deal. Any other type of cap raising, if even possible, will signal the end.
Expand
(20min delay)